1.
|
7 p, 525.4 KB |
Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma
/
Shiraishi, Kouya (National Cancer Center Research Institute (Tòquio, Japó)) ;
Okada, Yukinori (Tokyo Medical and Dental University) ;
Takahashi, Atsushi (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Kamatani, Yoichiro (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Momozawa, Yukihide (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Ashikawa, Kyota (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Kunitoh, Hideo (Japanese Red Cross Medical Center (Tòquio, Japó)) ;
Matsumoto, Shingo (National Cancer Center Research Institute (Tòquio, Japó)) ;
Takano, Atsushi (The University of Tokyo) ;
Shimizu, Kimihiro (Gunma University Hospital (Maebashi, Japó)) ;
Goto, Akiteru (Akita University (Akita, Japó)) ;
Tsuta, Koji (National Cancer Center Hospital (Tòquio, Japó)) ;
Watanabe, Shun-ichi (National Cancer Center Hospital (Tòquio, Japó)) ;
Ohe, Yuichiro (National Cancer Center Hospital (Tòquio, Japó)) ;
Watanabe, Yukio (National Cancer Center Hospital (Tòquio, Japó)) ;
Goto, Yasushi (National Cancer Center Hospital (Tòquio, Japó)) ;
Nokihara, Hiroshi (National Cancer Center Hospital (Tòquio, Japó)) ;
Furuta, Koh (National Cancer Center Hospital (Tòquio, Japó)) ;
Yoshida, Akihiko (National Cancer Center Hospital (Tòquio, Japó)) ;
Goto, Koichi (National Cancer Center Hospital East (Chiba, Japó)) ;
Hishida, Tomoyuki (National Cancer Center Hospital East (Chiba, Japó)) ;
Tsuboi, Masahiro (National Cancer Center Hospital East (Chiba, Japó)) ;
Tsuchihara, Katsuya (National Cancer Center Research Institute (Tòquio, Japó)) ;
Miyagi, Yohei (Kanagawa Cancer Center Research Institute (Yokohama, Japó)) ;
Nakayama, Haruhiko (Kanagawa Cancer Center (Yokohama, Japó)) ;
Yokose, Tomoyuki (Kanagawa Cancer Center (Yokohama, Japó)) ;
Tanaka, Kazumi (Gunma University Hospital (Maebashi, Japó)) ;
Nagashima, Toshiteru (Gunma University Hospital (Maebashi, Japó)) ;
Ohtaki, Yoichi (Gunma University Hospital (Maebashi, Japó)) ;
Maeda, Daichi (Akita University (Akita, Japó)) ;
Imai, Kazuhiro (Akita University (Akita, Japó)) ;
Minamiya, Yoshihiro (Akita University (Akita, Japó)) ;
Sakamoto, Hiromi (National Cancer Center Research Institute (Tòquio, Japó)) ;
Saito, Akira (StaGen Co., Ltd. (Tòquio, Japó)) ;
Shimada, Yoko (National Cancer Center Research Institute (Tòquio, Japó)) ;
Sunami, Kuniko (National Cancer Center Research Institute (Tòquio, Japó)) ;
Saito, Motonobu (National Cancer Center Research Institute (Tòquio, Japó)) ;
Inazawa, Johji (Tokyo Medical and Dental University) ;
Nakamura, Yusuke (University of Chicago) ;
Yoshida, Teruhiko (National Cancer Center Research Institute (Tòquio, Japó)) ;
Yokota, Jun (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Matsuda, Fumihiko (Kyoto University) ;
Matsuo, Keitaro (Aichi Cancer Center Research Institute (Nagoya, Japó)) ;
Daigo, Yataro (The University of Tokyo) ;
Kubo, Michiaki (RIKEN Center for Integrative Medical Sciences (Yokohama, Japó)) ;
Kohno, Takashi (National Cancer Center Research Institute (Tòquio, Japó))
Lung adenocarcinoma driven by somatic EGFR mutations is more prevalent in East Asians (30-50%) than in European/Americans (10-20%). Here we investigate genetic factors underlying the risk of this disease by conducting a genome-wide association study, followed by two validation studies, in 3,173 Japanese patients with EGFR mutation-positive lung adenocarcinoma and 15,158 controls. [...]
2016 - 10.1038/ncomms12451
Nature communications, Vol. 7 (August 2016) , art. 12451
|
|